Updates On Aflibercept BPCIA Litigation - Life Sciences, Bio

On Friday, January 20, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed an ex parte application for a scheduling order setting the schedule for preliminary injunction proceedings or, in the alternative, an emergency status conference.

Related Keywords

California , United States , Northern District , West Virginia , Samsung Bioepis , Celltrion Inc , Amgen , Regeneron Pharmaceuticals Inc , Amgen Inc , Judicial Panel , Us District Court , Samsung Bioepis Co , Judicial Panel On Multidistrict , Mylan Pharmaceuticals Inc , Biocon Biologics Inc , Regeneron Pharmaceuticals , Central District , Chief Judge Kleeh , Multidistrict Litigation , Mylan Pharmaceuticals , Big Molecule Watch , Mondaq , Aflibercept , Celltrion , Eylea , Formycon , Litigation , Regeneron , Egeneronv Amgen , Egeneronv Celltrion , Egeneronv Formycon , Regeneronv Mylan , Egeneronv Samsung Bioepis , Amsung Bioe , Food , Drugs , Healthcare , Life Sciences , Iotechnology Amp Nanotechnology , Intellectual Property , Patent , ,